Downregulation of INPP4B is Associated with Poor Prognosis in Epithelial Ovarian Carcinoma
DOI: https://doi.org/10.2147/ijgm.s445491
IF: 2.145
2024-03-19
International Journal of General Medicine
Abstract:Liangliang Jiang, Jing Wang Department of Gynecological Tumor, Harbin Medical University Cancer Hospital, Harbin, People's Republic of China Correspondence: Jing Wang, Department of Gynecological Tumor, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang Province, People's Republic of China, Tel +8646022627, Email Background: INPP4B is a tyrosine-specific phosphatase in the human body, which plays an important role in the developing process of carcinogenesis. However, The correlation between INPP4B and epithelial ovarian cancer is rarely explored. In this study, the expression of INPP4B in human epithelial ovarian carcinoma and normal ovaries was detected, to explore the correlation between INPP4B expression and clinicopathological risk factors of epithelial ovarian carcinoma and to clarify its significance in the developing process of and prognosis of epithelial ovarian carcinoma. Methods: The expression of INPP4B in various tumors was detected by bioinformatics method, and the expression in epithelial ovarian cancer and normal control group was detected by Elisa. The immunohistochemical method was used in this experiment to analyze the expression of INPP4B in specimens of 100 cases of epithelial ovarian carcinoma and 20 cases of normal ovaries. Analysis of clinicopathological risk factors and related survival analysis was carried out on the expression of INPP4B in 100 cases of epithelial ovarian carcinoma. Results: The results showed that the positive expressed INPP4B protein in epithelial ovarian carcinoma was significantly less, compared with that in normal ovaries (P < 0.05). The expression of INPP4B was significantly associated with many clinicopathologic factors, such as tumor differentiation (P < 0.001), FIGO stage (P < 0.001), lymph node metastasis (P < 0.001) and distant metastasis at recurrence (P=0. 009), but not with age, pathologic type of tumor, serum CA125 at recurrence and chemotherapy sensitivity. Conclusion: In epithelial ovarian carcinoma, there is a downregulation of INPP4B expression, which may be related to poor tumor differentiation, late FIGO stage, lymph node metastasis, distant metastasis at recurrence and insensitivity to chemotherapy. Under-expression of INPP4B, lymph node metastasis, FIGO stage, and distant metastasis at recurrence are factors of poor prognostic. The under-expression level of INPP4B may be involved in the progression of epithelial ovarian carcinoma. Keywords: epithelial ovarian carcinoma, INPP4B, immunohistochemistry: clinical significance, survival Epithelial ovarian carcinoma is one of the gynecological malignant tumors, with the third highest mortality rate after cervical cancer in the world. 1 Epithelial ovarian cancer has a genetic predisposition, and germline BRCA1/2 mutations are the strongest known genetic risk factor for epithelial ovarian cancer. The lifetime risk of ovarian cancer for carriers of germline mutations in the BRCA1 and BRCA2 genes is 35–60% and 12–25%, respectively. BRCA1/2 status can be used to predict a patient's expected survival. 2 Although the surgical procedure and chemotherapeutics have been improved, and the overall survival rate of patients with epithelial ovarian carcinoma has improved over the past 50 years, the five-year survival rate is still below 50%. 3 The cost of treatment per patient with ovarian cancer remains the highest among all types of cancer. For instance, the average initial cost in the first year can amount to approximately USD 80,000, while the final year cost may escalate to USD 100,000. 4 In order to mitigate mortality associated with ovarian cancer, public health experts are also seeking an economical and convenient screening strategy. Women with BRCA mutations have a significantly elevated lifetime risk of developing ovarian cancer, typically presenting as high-grade serous carcinoma which is highly aggressive and has a substantial mortality rate. Consequently, current treatment guidelines for epithelial ovarian cancer also encompass various preventive strategies for patients with hereditary ovarian cancer including genetic counseling for women at high risk and risk-reducing interventions (RRI) such as surgical procedures or chemoprevention through contraceptive medications. However, there still exist several unresolved challenges. Inositol polyphosphate-4-phosphatase type II (INPP4B) is a phosphoinositol phosphatase, which is a negative regulator of PI3K/AKT signaling pathway. 5 It is noteworthy to mention that the PI3K pathway is frequently upregulated in epithelial ovarian cancer and plays a pivotal role in chemoresistance and preservation of genomic stability, as it is implicated in numerous processes of DNA replication and cell cycle regulati -Abstract Truncated-
medicine, general & internal